Olubukola T Idoko

List of Publications by Year
in descending order

36 papers	894 citations	623734 14 h-index	501196 28 g-index
37 all docs	37 docs citations	37 times ranked	1546 citing authors

#	Article	IF	Citations
1	Bacille Calmette-GuÃ©rin vaccine reprograms human neonatal lipid metabolism inÂvivo and inÂvitro. Cell Reports, 2022, 39, 110772.	6.4	13
2	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Africa: Current Considerations and Future Projections. Clinical Infectious Diseases, 2022, 75, S136-S140.	5.8	3
3	A cloud-based bioinformatic analytic infrastructure and Data Management Core for the Expanded Program on Immunization Consortium. Journal of Clinical and Translational Science, 2021, 5, e52.	0.6	3
4	A scorecard of progress towards measles elimination in 15 west African countries, 2001â€“19: a retrospective, multicountry analysis of national immunisation coverage and surveillance data. The Lancet Global Health, 2021, 9, e280-e290.	6.3	28
5	Plasma Adenosine Deaminase (ADA)-1 and -2 Demonstrate Robust Ontogeny Across the First Four Months of Human Life. Frontiers in Immunology, 2021, 12, 578700.	4.8	7
6	Conducting clinical research in a resource-constrained setting: lessons from a longitudinal cohort study in The Gambia. BMJ Global Health, 2021, 6, e006419.	4.7	4
7	Ontogeny of plasma cytokine and chemokine concentrations across the first week of human life. Cytokine, 2021, 148, 155704.	3.2	4
8	Serological Protection 5â€“6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes. Frontiers in Immunology, 2020, 11, 577751.	4.8	5
9	Clinical Protocol for a Longitudinal Cohort Study Employing Systems Biology to Identify Markers of Vaccine Immunogenicity in Newborn Infants in The Gambia and Papua New Guinea. Frontiers in Pediatrics, 2020, 8, 197.	1.9	12
10	Zika Virus in West Africa: A Seroepidemiological Study between 2007 and 2012. Viruses, 2020, 12, 641.	3.3	13
11	The burden of viral respiratory infections in young children in low-resource settings. The Lancet Global Health, 2020, 8, e454-e455.	6.3	13
12	Antibody responses to yellow fever vaccine in 9 to 11-month-old Malian and Ghanaian children. Expert Review of Vaccines, 2019, 18, 867-875.	4.4	11
13	Dynamic molecular changes during the first week of human life follow a robust developmental trajectory. Nature Communications, 2019, 10, 1092.	12.8	151
14	Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines â€“ A phase II, randomised, observer-blind study in Gambian infants. Vaccine, 2019, 37, 2586-2599.	3.8	19
15	Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials. Lancet Infectious Diseases, The, 2019, 19, 327-336.	9.1	25
16	Tracking coverage, dropout and multidimensional equity gaps in immunisation systems in West Africa, 2000â€“2017. BMJ Global Health, 2019, 4, e001713.	4.7	26
17	Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial. Vaccine, 2017, 35, 3256-3263.	3.8	11
18	Recall and decay of consent information among parents of infants participating in a randomized controlled clinical trial using an audio-visual tool in The Gambia. Human Vaccines and Immunotherapeutics, 2017, 13, 2185-2191.	3.3	7

#	Article	IF	Citations
19	Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study. Vaccine, 2017, 35, 2531-2542.	3.8	71
20	Acceptance of multiple injectable vaccines in a single immunization visit in The Gambia pre and post introduction of inactivated polio vaccine. Vaccine, 2016, 34, 5034-5039.	3.8	8
21	Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme of Immunization in The Gambia. Vaccine, 2015, 33, 7144-7151.	3.8	48
22	Increased Disease due to Haemophilus influenzae Type b. Pediatric Infectious Disease Journal, 2015, 34, e107-e112.	2.0	18
23	Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials. Clinical Infectious Diseases, 2015, 61, S416-S421.	5.8	14
24	Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine. Clinical Infectious Diseases, 2015, 61, S422-S427.	5.8	9
25	Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2â€“29 Years. Clinical Infectious Diseases, 2015, 61, S521-S530.	5.8	17
26	Antibody Persistence 1â€“5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12â€“23 Months of Age. Clinical Infectious Diseases, 2015, 61, S514-S520.	5.8	13
27	Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays. Clinical Infectious Diseases, 2015, 61, S554-S562.	5.8	7
28	Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12â€“23 Months Following Meningococcal Vaccination. Clinical Infectious Diseases, 2015, 61, S563-S569.	5.8	5
29	Lessons in participant retention in the course of a randomized controlled clinical trial. BMC Research Notes, 2014, 7, 706.	1.4	13
30	Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: An open-label randomized controlled trial. Tuberculosis, 2014, 94, 564-578.	1.9	58
31	Development and Use of a Serum Bactericidal Assay Using Pooled Human Complement To Assess Responses to a Meningococcal Group A Conjugate Vaccine in African Toddlers. Vaccine Journal, 2014, 21, 755-761.	3.1	15
32	The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines. Vaccine, 2014, 32, 4220-4227.	3.8	14
33	Impact, Challenges, and Future Projections of Vaccine Trials in Africa. American Journal of Tropical Medicine and Hygiene, 2013, 88, 414-419.	1.4	24
34	Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans. New England Journal of Medicine, 2011, 364, 2293-2304.	27.0	155
35	Meningococcal Group C and W135 Immunological Hyporesponsiveness in African Toddlers. Vaccine Journal, 2011, 18, 1492-1496.	3.1	14
36	Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa. Vaccine, 2009, 27, 2023-2029.	3.8	15